New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring
Trinity Biotech announced clinical trial results validating its CGM+ wearable biosensor platform’s multi-sensor technology that effectively distinguishes false low glucose readings caused by nocturnal sensor compression from true lows. The data, based on over 5,000 hours of clinical wear, demonstrates improved accuracy and reduced false alarms in c…